The 17% dilution is material for a clinical-stage biotech with no approved products. Monitor for potential further dilution if the underwriters exercise the overallotment option. The stock may face near-term selling pressure as the market absorbs the new shares.
Price Chart
Executive Summary
Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, expecting gross proceeds of $150 million. The offering represents approximately 17% dilution based on the current market cap of $868M, and proceeds will fund clinical trials and R&D for its autoimmune pipeline.
Key Financial Metrics
Key Facts
- Pricing of 10,000,000 shares at $15.00 per share for gross proceeds of $150 million
- Underwriters have a 30-day option to purchase up to an additional 1,500,000 shares
- Offering expected to close on June 5, 2026
- Proceeds to fund clinical trials, preclinical studies, manufacturing, and general corporate purposes
- Lead candidate JADE101 targets APRIL for IgA nephropathy; pipeline also includes JADE201 and JADE301
- Offering is being made under an effective shelf registration statement (Form S-3) declared effective May 15, 2026
Financial Impact
Dilution of approximately 17% based on current market cap of $868M; gross proceeds of $150M
Risk Factors
- Dilution of ~17% from the offering, with potential additional dilution from the underwriters' option
- Clinical-stage company with no approved products; pipeline risk for JADE101, JADE201, and JADE301
- Proceeds used for R&D with no near-term revenue expectation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306490 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers